TNFRSF10B and Miyoshi myopathy: Bortezomib sensitizes MM cells to NK cells via upregulation of death receptor 5 (DR5) and selective reduction of HLA-E on MM cells, reducing the HLA-E-mediated immune escape in MM patients 104.